Halozyme Therapeutics Inc (HALO)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 281,594 | 253,908 | 233,705 | 181,636 | 202,129 | 211,197 | 366,150 | 434,923 | 402,710 | 409,104 | 228,724 | 163,083 | 129,085 | 21,524 | -39,698 | -80,139 | -72,240 | -39,969 | -42,804 | -51,073 |
| Total stockholders’ equity | US$ in thousands | 83,808 | 249,181 | 151,033 | 65,850 | 169,798 | 96,991 | 293,171 | 260,256 | 196,953 | 281,674 | 119,746 | 67,595 | 151,047 | 98,988 | 105,577 | 58,042 | 91,765 | 245,353 | 260,052 | 260,047 |
| ROE | 336.00% | 101.90% | 154.74% | 275.83% | 119.04% | 217.75% | 124.89% | 167.11% | 204.47% | 145.24% | 191.01% | 241.26% | 85.46% | 21.74% | -37.60% | -138.07% | -78.72% | -16.29% | -16.46% | -19.64% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $281,594K ÷ $83,808K
= 336.00%
To analyze Halozyme Therapeutics Inc.'s return on equity (ROE) based on the data provided, we observe significant fluctuations in ROE over the past eight quarters. ROE is a measure of a company's profitability that highlights how effectively a company generates profit from its equity.
In Q4 2023, Halozyme Therapeutics Inc. reported a remarkably high ROE of 336.00%, signifying strong efficiency in utilizing equity to generate profit. This substantial increase from the previous quarter's ROE of 101.90% indicates a significant improvement in profitability.
The company's ROE in Q3 2023, Q2 2023, and Q1 2023 stood at 101.90%, 154.74%, and 275.83%, respectively. These figures demonstrate a fluctuating trend in profitability over these quarters, with Q1 2023 showing the highest ROE during this period.
Comparing the recent quarters to the same periods in 2022, we see varying levels of ROE. Q4 2023 exhibited a notable increase compared to Q4 2022, whereas Q3 2023 showed a decline from the previous year's corresponding quarter.
Overall, Halozyme Therapeutics Inc. has experienced fluctuations in its return on equity over the past eight quarters, with Q4 2023 recording a particularly high ROE. Further analysis would be beneficial to understand the factors driving these changes and to assess the sustainability of the company's profitability performance.
Peer comparison
Dec 31, 2023